Lack of involvement of nitric oxide in the macrophage-mediated inhibition of spleen cell proliferation during experimental cryptococcosis.
We investigated the proliferative response to mitogens of spleen mononuclear (Spm) cells from Cryptococcus neoformans-infected rats. We determined reactive oxygen intermediates (ROI) and nitric oxide (NO) production by peritoneal and Spm cells, and evaluated the correlation of the proliferative response with NO and ROI production. The proliferative response of Spm cells from infected rats dramatically decreased at 14 and 21 days postinfection (PI). The unresponsiveness of Spm cells from 14-day infected rats was not abrogated by the addition of L-NAME and AG, indicating that NO is not involved in the antiproliferative response of experimental cells. When SOD, catalase, and indomethacin were added to the cultures, the suppression was still observed, indicating that ROI and prostaglandins are not involved in the unresponsiveness of lymphocytes. The proliferative response of lymphocytes from 14-day infected rats was significantly improved when cultures were made in the presence of Con A and exogenous IL-2. Additionally, a purified T-rich fraction from infected rats cultured with control macrophages recovered the normal proliferative response. This result indicates that macrophages from infected rats mediate the unresponsiveness of lymphocytes, probably by reducing the ability of lymphocytes to secrete IL-2.
Rossi
G R
GR
Micología Departamento Bioquímica Clínica, Fac. Ciencias Químicas, Universidad Nacional de Córdoba, Argentina.
Cervi
L A
LA
Sastre
D A
DA
Masih
D T
DT
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D002374:Catalase / Q000494:pharmacology; D003208:Concanavalin A / Q000494:pharmacology; D003453:Cryptococcosis / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006146:Guanidines / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007376:Interleukin-2 / Q000378:metabolism / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000502:physiology*; D016131:Lymphocyte Subsets / Q000166:cytology / Q000276:immunology*; D017737:Macrophages, Peritoneal / Q000502:physiology*; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000494:pharmacology; D012636:Secretory Rate / Q000187:drug effects; D013154:Spleen / Q000166:cytology*; D013482:Superoxide Dismutase / Q000494:pharmacology
D000975:Antioxidants; D004791:Enzyme Inhibitors; D006146:Guanidines; D007376:Interleukin-2; D008070:Lipopolysaccharides; D011448:Prostaglandin Antagonists; D011994:Recombinant Proteins; D003208:Concanavalin A; D009569:Nitric Oxide; D002374:Catalase; D019001:Nitric Oxide Synthase; D013482:Superoxide Dismutase; C004479:pimagedine; D019331:NG-Nitroarginine Methyl Ester; D007213:Indomethacin